Cardio Diagnostics (CDIO) vs Q/C Technologies (QCLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardio Diagnostics is the larger company by market cap ($5.8 million vs $5.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | CDIO | QCLS |
|---|---|---|
| Share price | $1.96 | $0.632 |
| Market cap | $5.80M | $5.18M |
| 1-day change | -2.00% | -8.42% |
| P/E ratio (TTM) | — | 0.24 |
| EPS (TTM) | $-2.87 | $2.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.91 | $8.17 |
| 52-week low | $0.97 | $0.42 |
| Distance from 52-week high | -75.22% | -92.26% |
| Average volume | 55.78K | 5.05M |
| Shares outstanding | 2.96M | 8.19M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
CDIO vs QCLS FAQ
Which is bigger, Cardio Diagnostics or Q/C Technologies?
Cardio Diagnostics (CDIO) is larger, with a market capitalization of $5.80M compared with $5.18M for Q/C Technologies (QCLS).
Are Cardio Diagnostics and Q/C Technologies in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.